Levetiracetam
- Createtime： 2026-04-14
- Updatetime： 2026-04-15
Product Details
| useage |
Industrial use
|
| deliveryInfo |
|
| appearance |
powder
|
| Molecular Weight |
170.21
|
| aliasen |
|
| supplyCapacity |
50000MT/Month
|
| harbor |
Qingdao,China
|
| minorder |
1KG
|
| Appearance |
White to off-white crystalline powder
|
Shandong Huashang Chemical Co., Ltd. is a high-tech enterprise specializing in the research and development, manufacturing, and sales of fine chemicals. Headquartered in Jinan, Shandong, China, we are committed to delivering high-quality products to our global partners. Currently, over 90% of our products are exported to developed markets, including North America, Europe, Japan, South Korea, and the Middle East.
Basic Information
Product Name: Levetiracetam
Alias: (S)-α-Ethyl-2-oxo-1-pyrrolidineacetamide; 2(S)-(2-Oxopyrrolidin-1-yl)butyramide; Keppra
CAS No.: 102767-28-2
EINECS No.: 600-348-9
Molecular Formula: C?H??N?O?
Molecular Weight: 170.21 g/mol
Classification: Antiepileptic drug (AED); Pyrrolidine derivative; Pharmaceutical API; CNS agent
Physical & Chemical Properties
Appearance: White to off-white crystalline powder
Density: 1.168 g/cm3
Melting Point: 112–115 °C
Boiling Point: 239.8 °C (760 mmHg)
Refractive Index: 1.518
Solubility: Soluble in water (≈100 mg/mL at 25 °C); soluble in ethanol, methanol; slightly soluble in acetone
Specific Rotation: [α]2?D ?90° to ?94° (c=1, water)
Storage: 2–8 °C, sealed, dry place
Specification Table
| Item | Specification | Unit | Remarks |
| Product Name | Levetiracetam | — | API |
| CAS Number | 102767-28-2 | — | — |
| Appearance | White crystalline powder | — | Odorless |
| Molecular Formula | C?H??N?O? | — | — |
| Molecular Weight | 170.21 | g/mol | — |
| Purity | ≥99.0 | % | HPLC |
| Loss on Drying | ≤0.5 | % | — |
| Residue on Ignition | ≤0.1 | % | — |
Main Uses
- Antiepileptic Treatment: Monotherapy or adjunctive therapy for partial-onset seizures, myoclonic seizures, and generalized tonic-clonic seizures in adults and children.
- Mechanism: Binds to synaptic vesicle protein SV2A, modulating neurotransmitter release and stabilizing neuronal excitability.
- Adjuvant in Oncology: Investigated for enhancing temozolomide efficacy in glioblastoma by epigenetic silencing of MGMT.
- Neurological Research: Tool compound for studying SV2A function, epilepsy mechanisms, and CNS drug development.
